People
Vanessa Yen is a partner and trial lawyer in the Intellectual Property, Patent, Trademark and Copyright Litigation group. She focuses her practice on complex, high-stakes patent litigations, and intellectual property transactions, counseling, and disputes. Vanessa has never lost a trial on behalf of her clients. Considered one of the “world’s leading patent professionals” with “exceptional skill sets and profound insights into patent matters” while “maintaining clear strategic vision,” Vanessa was recognized as such by IAM Patent 1000.
As an MIT graduate, Vanessa is focused on handling intellectual property patent matters for clients in the technology, life sciences, pharma, and chemical industries. Vanessa’s representative clients and matters includes work done for companies from around the world, such as: GlaxoSmithKline, GW Pharma, Alexion, Bristol Myers Squibb, Galderma, Sword Health, Sunovion, Shire LLC, Supernus, AstraZeneca, Gilead, UCB, Celltech, Eisai, Canon and Novartis.
Experienced with bench and jury patent trials before U.S. district courts, the U.S. Court of Appeals for the Federal Circuit and the PTAB, Vanessa has deep litigation experience handling pharmaceutical and biologics/biosimilars patent litigations, including for blockbuster products with multi-billion dollar sales. She has handled IP matters concerning various technologies, including products and treatments for cancer, HIV/AIDS, skin care and dermatology, femtech, prostate disorders, genetic vector technology and molecular cloning, musculoskeletal disorders, autoimmune and neurological disorders.
Named as one of the Top Women Attorneys in New York metro and a Top Rated Intellectual Property Litigation Attorney, Vanessa provides her clients with an array of IP services beyond patent litigation, including licensing and due diligence advice, strategic assessment of IP assets and IP portfolios for potential mergers & acquisitions, freedom to operate opinions, and others.
Vanessa has handled one of the Top Litigations and Disputes of 2019 (recognized by Financial Times) and achieved a patent litigation victory that was named Hatch Waxman Impact Case of the Year (recognized by LMG Life Sciences). She was also part of the team that obtained the first IPR victory for an Orange Book-listed patent dispute that was involved in parallel Federal district court litigation.
Committed to diversity and inclusion, Vanessa co-leads K&S's Asian Affinity Group, and is an active member of NAPABA, GABAPA, AALDEF and AABANY.
Prior to law, Vanessa spent years conducting breast cancer research and genetics/genomic research while at MIT. She also worked at a top U.S. strategic management consulting firm.
J.D., Cornell Law School
B.S., Massachusetts Institute of Technology
New Jersey
New York
U.S. Court of Appeals for the Federal Circuit
AABANY
AALDEF
ChIPs
GAPABA
NAPABA
National Association of Women Lawyers
New York Intellectual Property Law Association
Cantonese Hong Kong
Mandarin Chinese
Alexion Pharmaceuticals in several patent litigation disputes before the PTAB involving Soliris®, a multi-billion dollar biologic product
Bristol Myers Squibb in connection with a patent litigation involving CAR-T related biotech for cancer immunotherapy; in connection with patent litigation dispute matters for BMS's other cancer therapies
Galderma in a patent litigation and IPRs involving Oracea®, a product for rosacea with over a billion dollars in sales
See more
September 1, 2021
“Purple Book” Patent Listing Under Biological Product Patent Transparency Act: What Is Required, and What to Expect?
April 7, 2021
“Purple Book” Patent Listing Under Biological Product Patent Transparency Act: What is Required, and What to Expect?
February 12, 2021
GSK v. Teva and Induced Infringement by AB-Rated Generics: Where are we now?
Alexion Pharmaceuticals in several patent litigation disputes before the PTAB involving Soliris®, a multi-billion dollar biologic product
Bristol Myers Squibb in connection with a patent litigation involving CAR-T related biotech for cancer immunotherapy; in connection with patent litigation dispute matters for BMS's other cancer therapies
Galderma in a patent litigation and IPRs involving Oracea®, a product for rosacea with over a billion dollars in sales
See more
September 1, 2021
“Purple Book” Patent Listing Under Biological Product Patent Transparency Act: What Is Required, and What to Expect?
April 7, 2021
“Purple Book” Patent Listing Under Biological Product Patent Transparency Act: What is Required, and What to Expect?
February 12, 2021
GSK v. Teva and Induced Infringement by AB-Rated Generics: Where are we now?
J.D., Cornell Law School
B.S., Massachusetts Institute of Technology
New Jersey
New York
U.S. Court of Appeals for the Federal Circuit
AABANY
AALDEF
ChIPs
GAPABA
NAPABA
National Association of Women Lawyers
New York Intellectual Property Law Association
Cantonese Hong Kong
Mandarin Chinese